Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Tramadol and methadone users are at increased risk of hypoglycaemia, study reveals

Researchers hope their findings will motivate research about the unique molecular mechanism leading to hypoglycaemia as a side effect of taking tramadol and methadone.

Tramadol capsules


Researchers found that the frequency of hypoglycaemia reports in tramadol users was more than ten times higher than for users of other opioids

Patients who take tramadol and methadone are at a higher risk of developing hypoglycaemia compared to those who take other opioids, a study published in Scientific Reports (28 August 2019) has found[1].

Researchers analysed more than 12 million adverse event reports from the US Food and Drug Administration’s Adverse Event Reporting System to generate a risk profile of tramadol’s association with hypoglycaemia when compared to other opioids.

Most of the adverse drug reactions reported in the tramadol cohort were common to the opioid class, including dizziness, headaches and vomiting. Side effects that were unique to tramadol included convulsions and seizures.

The researchers also found that the frequency of hypoglycaemia reports in tramadol users was more than ten times higher than for users of other opioids (1.13% vs 0.10%), such as codeine, morphine and fentanyl. 

Of the other ten opioids analysed, only methadone was found to also be linked to an increased frequency of hypoglycaemia reports (0.87%)

As a result, the authors said that it may be beneficial to monitor glucose levels when initiating tramadol or methadone in both patients with diabetes and without diabetes. 

“The takeaway message is to warn physicians about the likelihood of low blood sugar (and/or high insulin content) — in particular if the patient is predisposed to diabetes,” said Ruben Abagyan, professor of pharmacy at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California, San Diego. 

“[We hope it will] motivate research about the unique molecular mechanism leading to that side effect. It is particularly important for tramadol or methadone that are used widely and, often, chronically.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20207003

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.